Further, the first-in-class anti-KIR3DL2/CD158k humanized NK-mediated ADCC-inducing antibody lacutamab (IPH4102), designed to selectively destroy CTCL cancer cells, presents a compelling option62. This evidence concerns the gene KIR3DL2 and cancer.